D&D Pharmatech Inc. (KOSDAQ:347850)

D&D Pharmatech Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	26,147	30,014	15,642	25,504	75,958	60,612
Cash & Short-Term Investments	26,147	30,014	15,642	25,504	75,958	60,612
Cash Growth	67.16%	91.88%	-38.67%	-66.42%	25.32%	-46.39%
Accounts Receivable	136.77	3,141	263.95	41.84	12.46	0.93
Other Receivables	3,190	2,383	1,165	286.31	94.12	30.84
Receivables	3,327	5,524	1,429	328.15	106.58	31.76
Prepaid Expenses	3,402	4,047	2,356	7,330	5,507	5,734
Other Current Assets	181.3	209.3	138.64	193.46	121.45	166.43
Total Current Assets	33,057	39,794	19,565	33,355	81,692	66,544
Property, Plant & Equipment	7,337	7,729	6,422	3,024	10,966	8,147
Long-Term Investments	13,376	14,242	10,776	12,326	-	-0
Goodwill	2,088	2,093	9,905	9,735	34,754	31,895
Other Intangible Assets	31,516	32,476	31,615	34,246	122,689	121,775
Long-Term Accounts Receivable	3.28	3.84	179.43	6.72	7.68	-
Other Long-Term Assets	1,152	1,162	740.73	948.44	1,000	800.14
Total Assets	88,530	97,500	79,204	93,642	251,109	229,161
Accrued Expenses	3,036	4,468	2,080	6,803	7,647	4,871
Short-Term Debt	916.99	1,830	1,521	19,225	34,836	-
Current Portion of Leases	1,860	1,772	1,493	1,583	1,276	712.19
Other Current Liabilities	3,517	3,044	2,393	27,312	23,100	3,558
Total Current Liabilities	9,330	11,115	7,487	54,923	66,859	9,141
Long-Term Debt	-	-	-	-	-	529.51
Long-Term Leases	5,759	6,180	5,121	6,425	7,463	4,488
Long-Term Deferred Tax Liabilities	8,610	8,811	8,564	9,239	33,367	33,122
Other Long-Term Liabilities	1,651	1,825	2,801	4,536	5,042	312.79
Total Liabilities	25,350	27,931	23,986	75,123	112,781	47,854
Common Stock	5,354	5,284	4,649	4,034	4,028	4,019
Additional Paid-In Capital	342,951	337,015	297,522	268,925	268,673	266,338
Retained Earnings	-319,211	-309,361	-289,676	-293,610	-157,543	-89,319
Comprehensive Income & Other	34,831	37,174	34,154	30,091	16,951	-204.76
Total Common Equity	63,924	70,112	46,650	9,440	132,109	180,833
Minority Interest	-744.59	-542.93	8,568	9,079	6,219	474.03
Shareholders' Equity	63,180	69,569	55,218	18,519	138,328	181,307
Total Liabilities & Equity	88,530	97,500	79,204	93,642	251,109	229,161
Total Debt	8,536	9,782	8,134	27,233	43,575	5,730
Net Cash (Debt)	17,611	20,231	7,508	-1,729	32,383	54,881
Net Cash Growth	134.57%	169.47%	-	-	-40.99%	-50.35%
Net Cash Per Share	1682.62	1995.45	800.35	-214.55	3935.19	7513.43
Filing Date Shares Outstanding	10.71	10.57	9.3	8.07	8.06	8.04
Total Common Shares Outstanding	10.71	10.57	9.3	8.07	8.06	8.04
Working Capital	23,727	28,680	12,078	-21,568	14,834	57,403
Book Value Per Share	5970.15	6634.34	5016.66	1170.20	16397.46	22498.20
Tangible Book Value	30,320	35,544	5,129	-34,541	-25,333	27,163
Tangible Book Value Per Share	2831.69	3363.29	551.59	-4281.72	-3144.37	3379.44
Machinery	3,193	3,198	3,250	3,441	3,454	1,945
Construction In Progress	20.42	-	1.7	-	4.78	1,019

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.